BDX

$162.49+2.22 (+1.39%)

Market OpenAs of Mar 17, 7:14 PM UTC

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$162.49
Potential Downside
27%
Whystock Fair Value$118.68
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Instruments & Supplies

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$58.87B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
26.55
Beta
Defensive asset. Lower volatility than the S&P 500.
0.31
Div Yield
Strong income play. Yield provides a meaningful total return floor.
262.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
6.96%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.37

Recent News

Simply Wall St.
Mar 15, 2026

Assessing Becton Dickinson’s Valuation After Recent Share Weakness And Planned Business Separation

What recent returns say about Becton Dickinson (BDX) Becton Dickinson (BDX) has been under pressure, with the share price showing a 0.2% decline over the past day, about 4.6% over the past week, and roughly 9.4% over the past month. See our latest analysis for Becton Dickinson. The recent weakness is not just a short blip, with a 90 day share price return of 20.4% and an 18.3% year to date share price decline feeding into a 1 year total shareholder return of 8.2% and softer multi year...

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
StockStory
Mar 13, 2026

3 Healthcare Stocks Walking a Fine Line

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8% return has closely followed the S&P 500.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 12, 2026

Becton, Dickinson Recieves FDA Clearance for Surgiphor 1000 ml Irrigation System

Becton, Dickinson and Company (NYSE:BDX) is included among the 13 Undervalued Dividend Aristocrats to Buy Now. Becton, Dickinson and Company (NYSE:BDX) is one of the world’s largest pure-play medical technology companies in the world. BD drives innovation across medical essentials, connected care, biopharma systems, and interventional. Becton, Dickinson and Company (NYSE:BDX) announced on March 2 […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 11, 2026

Why Is Becton Dickinson (BDX) Down 4.5% Since Last Earnings Report?

Becton Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

NEUTRAL
Neutral flow. Standard news cycle with no clear sentiment tilt.
Motley Fool
Mar 8, 2026

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $1,000

This Dividend King is out of favor, and this medical device peer has just introduced an exciting new product.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.